The U.S. FTC reaches settlement in post-Actavis reverse payment case (Cephalon)

This article has been nominated for the 2016 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards.

The Federal Trade Commission (“FTC”) has reached a settlement resolving its claims that Cephalon, Inc. violated the antitrust laws by entering into reverse payment settlements to delay generic competition for Provigil. This is the first FTC settlement of a reverse payment case post-Actavis, and contains the largest disgorgement award in FTC history: $1.2 billion. The settlement, which was reached on the eve of trial, caps a lengthy litigation over Cephalon’s payments to four generic drug manufacturers. The Commission voted unanimously to approve the settlement, and it was filed with the court on May 28, 2015. The details of the settlement and the commissioners’ statements in support provide insight into the FTC’s approach to equitable monetary relief. The commissioners remain bitterly

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

Citation

Richard G. Parker, Kenneth R. O'Rourke, Ted Hassi, Anna Fabish, The U.S. FTC reaches settlement in post-Actavis reverse payment case (Cephalon), 28 mai 2015, e-Competitions May 2015, Art. N° 79670

Visites 148

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues